Enrich Biosystems News
Enrich Biosystems Attends 4th Annual Cell Therapy Potency Assay Summit on March 12-13, 2025
March 11, 2025
Branford, CT
Enrich Biosystems is thrilled to participate in the 4th Annual Cell Therapy Potency Assay Summit at the Hilton Boston Back Bay in Boston, MA, on March 12-13. The 2025 Summit is the premier event for analytical development and quality control teams focused on advancing cell therapy potency assay methodologies. This year, we’re bringing together industry leaders to tackle the key challenges in assay strategy and explore innovative technologies that can enhance your daily research activities.
The 4th Cell Therapy Potency Assay Summit enhances quality control content and a balanced focus across cell types and disease indications. You can gain insights from experts on the latest advancements in cell potency assay development, and discover our cutting-edge technologies for potency assay quantification to enhance accuracy.
We’re eager to share our innovative fluidics-free system and streamlined workflow, which help deep dive into quality control strategies with increased content to ensure product consistency and reduce batch variability. At Enrich Biosystems, we take great pride in our cell enrichment platform, designed to enrich out the most promising cell populations with the potential to make a real difference in patients’ lives.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Welcomes Dr. Laszlo Radvanyi as Scientific Advisor
BRANFORD, Conn., March 6, 2025 -- Enrich Biosystems, a Branford-based life science tool company, today announced the appointment of Laszlo G Radvanyi, Ph.D. as scientific advisor. Dr. Radvanyi, a Professor in the Department of Immunology at the University of Toronto, will help Enrich accelerate the commercialization of the company's microfluidics-free cell analysis and retrieval technology.
Enrich is driving the future of tumor-killing T-cell discovery with Enrich TROVO. This cutting-edge, microfluidics-free system preserves natural cell activity while enabling rapid high-throughput coculture and real-time analysis of countless T-cell clones—requiring minimal human intervention. TROVO's innovative AI-driven grouping effortlessly identifies the most promising T cell clones, eliminating user variability in selection and enhancing lab efficiency.
"Dr. Radvanyi brings a wealth of experience in fundamental and translational research in cancer immunotherapy to Enrich, making him an exceptional scientific advisor for our company," said Dong Wang, CEO at Enrich Biosystems. "As we embark on an exciting journey to expand our application portfolios, his expertise will be instrumental in driving us towards market success."
As founding CSO at Lion Biotechnologies (later renamed Iovance Biotherapeutics), the first biotech company to commercialize tumor-infiltrating lymphocyte (TIL) therapies for cancer, Dr. Radvanyi built a skilled scientific team and established the research infrastructure helping to guide the company into its early clinical trials. Dr. Radvanyi recently served as President & Scientific Director of the Ontario Institute for Cancer Research (OICR). Prior to this, he held positions at EMD Serono (Merck KGaA) as Senior Vice President and Global Head of Immuno-Oncology (IO) and at the University of Texas MD Anderson Cancer Center as a Professor in the Department of Melanoma Medical where he conducted fundamental and translational research in cancer immunotherapy.
"I'm incredibly excited to be joining the Enrich team and helping facilitate the development and commercialization of these unparalleled powerful cell discovery and clone retrieval technology for cell therapy research," said Dr. Radvanyi. "With this unparalleled technology, we're on the brink of major breakthroughs in drug and cell therapy discovery. I look forward to working with the team to unlock new possibilities for cell biologists and cell therapists."
Dr. Radvanyi holds a BSc, MSc, and PhD from the University of Toronto.
About Enrich Biosystems Inc.:
Enrich Biosystems is an emerging biotech company focused on developing and commercializing a groundbreaking microfluidics-free cell analysis and retrieval technology. This advanced cell technology transforms the workflow for cell coculturing, kinetics profiling, and clone retrieval, enabling efficient cell sorting processes based on desired clone behaviors and functions. Enrich collaborates with esteemed research institutions and cell therapy developers to enhance critical applications of its platform, including advancements in T-cell, NK cell, and stem cell therapy discovery. The company's TROVO platform has already gained traction among US and European customers.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends SLAS2025 International Conference & Exhibition on January 26-29, 2025
January 23, 2025
Branford, CT
Enrich Biosystems is excited to participate in the SLAS2025 International Conference & Exhibition at the San Diego Convention Center in San Diego, CA on January 26-29.
This year, we invite you to explore our award-winning TROVO system, designed to enhance your team's discoveries in T-cell and B-cell research. Join us at Booth #3259, and let's work together to elevate your research experience!
SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and developers and providers of laboratory automation technology and tools. Biologists, technologists, engineers and researchers unite across disciplines to build on their curiosity. The successful translation of this discovery is accelerated by advances in laboratory innovation and by providing education and information to transform research.
We’re eager to share our newest innovative workflows on high-throughput B-cell screening for antibody discovery as well as time-lapse micro-culture AI analysis, that bridge the critical gap of scaleability and accuracy of cell therapy development. At Enrich Biosystems, we take great pride in our fluidics-free cell discovery platform, designed to identify and isolate the most promising constructs with the potential to make a real difference in patients’ lives.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich TROVO Recognized With BioTech Breakthrough’s “Cell Sorting Product of the Year”!
November 19, 2024
Branford, CT
For more information:
BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, today announced that Enrich Biosystems, a pioneering early-stage biotech company developing a unique microfluidics-free cell analysis and retrieval technology, has received “Cell Sorting Product of the Year” for TROVO in the fourth annual BioTech Breakthrough Awards program.
Enrich’s novel cell discovery and retrieval platform, TROVO, enables a streamlined workflow of large-scale micro-coculturing, kinetics profiling, and non-fluidic cell sorting based on cell behavior and function. This groundbreaking high-throughput cell discovery platform provides long-term time-lapse cellular imaging, cell behavior analysis, and microfluidics-free clone retrieval.
TROVO offers innovative assay setups featuring microwell creation, micro-culture observation, and movie-guided clone retrieval, empowering users to design experiments that closely mimic real biological conditions and enhance data reliability. The microwell assay mode allows for creating up to 28,000 custom microwells of various sizes and shapes on a standard 6-well culture plate, providing remarkable flexibility and scalability. By eliminating microfluidic channels and tubing, TROVO addresses potential clogging issues caused by cell clumping and debris. This approach supports normal cell culture conditions for both suspension and adherent cells and can effectively simulate desired tumor microenvironments. Moreover, TROVO safeguards cells by minimizing the need for excessive force, shearing, or harsh enzymatic treatments commonly associated with microfluidics technology. Importantly, it operates seamlessly with standard cell culture plates under normal culture conditions, eliminating the requirement for costly consumables linked to other microfluidics systems for growing, running, and analyzing samples.
TROVO's research applications encompass a range of impactful areas, including the discovery of T cell therapies (such as TCR-T, TIL, and CAR-T), tumor resistance analysis, the isolation of rare cells, tumor cell line development, and sample processing in the field of cell and gene therapy. The Enrich team actively collaborates with research institutions and industry partners to advance vital applications for its platform, enhancing our collective capabilities in this important field.
“Thank you to BioTech Breakthrough for the ‘Cell Sorting Product of the Year’ award. It’s a great honor to receive recognition for our technology's ability to standardize cell discovery, and TROVO's unmatched technical features make it a game-changer for the cutting-edge discovery of cell therapy,” said Dong Wang, CEO at Enrich Biosystems. “We’re eager to keep enhancing our innovative fluidics-free system and powerful workflow, which helps to bridge the critical gap between in-vitro and in-vivo phases of cell therapy development. We believe TROVO has the potential to tremendously impact cell therapy research by significantly reducing process time and cost.”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets today. This year’s program attracted thousands of nominations from over 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
“TROVO allows cells to be monitored under native culture conditions, enabling fully controllable experimental timelines and cell behavior analysis. Although technologies have been developed to isolate cells of interest from a heterogeneous sample, they are often expensive and difficult to use, and isolating cells of interest usually comes with clogging and impaired cell viability,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “Enrich’s fluidics-free, retractable microwells, and visual enrichment strategies eliminate the pain points of existing cell sorting technologies and enable large-scale, low-cost, and highly reliable cell-based biomedical discovery. TROVO’s ultimate flexibility with design tools and modes enables you to design experiments to fit your unique research applications in order to develop novel cellular therapeutics.”
About Enrich Biosystems
Enrich Biosystems Inc., based in Branford, CT, is an emerging biotech company focused on developing and commercializing a groundbreaking microfluidics-free cell analysis and retrieval technology.
This advanced cell technology transforms the workflow for cell coculturing, kinetics profiling, and clone retrieval, enabling efficient cell sorting processes based on desired clone behaviors and functions. Enrich collaborates with esteemed research institutions and cell therapy developers to enhance critical applications of its platform, including advancements in T-cell, NK cell, and stem cell therapy discovery. The company’s TROVO platform has already gained traction among customers across the US and Europe.
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends SITC 2024 Annual Meeting on November 8-10, 2024
November 5, 2024
Branford, CT
Enrich Biosystems is thrilled to participate in the SITC 2024 Annual Meeting at the George R. Brown Convention Center in Houston, TX, on November 8-10. Enrich team has put in tremendous effort to enhance our TROVO system, which aims to advance global CGT discovery. We invite you to visit booth #546 to explore our system and discover our latest applications and data in TCR-T, TIL, and CAR-T research.
SITC 2024 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. SITC 2024 also includes updates on major national and international initiatives from academia, government, industry, and important society projects.
We’re eager to share our innovative fluidics-free system and streamlined workflow, which help bridge the critical gap between in-vitro and in-vivo phases of cell therapy development. At Enrich Biosystems, we take great pride in our cell discovery platform, designed to identify and isolate the most promising constructs with the potential to make a real difference in patients’ lives.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends the 6th Annual TIL Therapies Summit on October 22-24, 2024
October 21, 2024
Branford, CT
Enrich Biosystems is genuinely excited to participate in the 6th Annual TIL Therapies Summit at The Colonnade in Boston, MA, on October 16-17. We invite you to visit our booth as we come together at this important gathering dedicated to the future of TIL therapies for melanoma and beyond.
This summit provides a unique opportunity to connect with compassionate industry leaders who are working tirelessly to overcome challenges in cell expansion, engineering, characterization, and selection. We believe in the power of collaboration to drive progress in our field.
We’re eager to share our innovative fluidics-free system and streamlined workflow, which help bridge the critical gap between in-vitro and in-vivo phases of cell therapy development. At Enrich Biosystems, we take great pride in our cell discovery platform, designed to identify and isolate the most promising constructs with the potential to make a real difference in patients’ lives.
Whether your team is at the leading edge of this approach or you’re seeking to deepen your understanding to enhance your existing pipelines, Enrich team will see you in this valuable space for sharing insights and brainstorming effective, compassionate TIL discovery solutions for those affected by melanoma and beyond. Let’s work together to inspire hope and drive meaningful advancements in patient care.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends 2024 Advancing Gene and Cell Therapies for Cancer Conference on October 16-17, 2024
October 14, 2024
Branford, CT
Enrich Biosystems is trilled to join the 2024 Advancing Gene and Cell Therapies for Cancer event at the Wyndham Philadelphia Historic District on Oct. 16-17
Come visit our booth for an unparalleled opportunity to immerse yourself in the latest development and applications of our technology related to T-cell therapies. We are excited to share how our fluidics-free system and streamlined experiment workflow bridge the gap between in-vitro and in-vivo phases of cell therapy development. At Enrich Biosystems, we take pride in offering a cell discovery platform that has proven to identify and isolate the most promising constructs with the best in-vivo potential from an in-vitro screening or enrichment processes.
The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society’s members are scientists, physicians, patient advocates, and other professionals.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends the Bioprocessing Summit 2024 on August 19-22, 2024
August 18, 2024
Branford, CT
Enrich Biosystems is trilled to join the Bioprocessing Summit 2024, taking place August 19-22, 2024.
Come visit our booth at the Sheraton Boston Hotel in Boston, MA. We are excited to share how our microfluidics-free TROVO instrument and cell therapy discovery workflow are bridging the gap in current screening technologies for cell therapy development. At Enrich Biosystems, we take pride in offering a cell discovery platform that has proven to identify and isolate the most promising constructs with the best in-vivo potential.
This summit brings together thought leaders and pioneers in bioprocess R&D, scale-up, quality, and analytics. Explore cutting-edge research, exchange insights with industry experts, and chart the course for advancements that will shape the future of bioprocessing.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends the global cell & gene therapy summit 2024 on July 08-10, 2024
July 7, 2024
Branford, CT
Enrich Biosystems is excited to join the Global Cell & Gene Therapy Summit on July 08-10.
Come visit our booth and be part of our exciting presentation at the Boston Marriott Newton Hotel in Boston, MA on July 08-10, 2024. Discover how our TROVO platform can expedite your CGT research in academic labs as well as industrial settings.
This International Summit on Cell and Gene Therapy serves as a platform to explore the fundamental concepts of these transformative therapies. The summit brings together experts from academia and industry to discuss a range of topics related to cell and gene therapy, including ethical considerations, social implications, tools, techniques, marketing strategies, and the commercialization of cell and gene therapy products. It also showcases the latest research progress in CGT and explores opportunities for further enhancements in availability and productivity of these therapies. By fostering collaboration and knowledge exchange, the summit aims to advance the field of cell and gene therapy, benefiting patients worldwide.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends American Society of Gene and Cell Therapy 27th Annual Meeting on May 07-11, 2024
May 7, 2024
Branford, CT
Enrich Biosystems is excited to join ASGCT 27th Annual Meeting in Baltimore, MD on May 07-11.
Come by booth #1618 from May 7 to 11 to learn how our TROVO platform can accelerate your CGT research in both of academic labs and industrial settings.
The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society’s members are scientists, physicians, patient advocates, and other professionals. The ASGCT Annual Meeting is the premier event for gene and cell therapy professionals. The meeting is the best place for people in the field to learn from the latest scientific research, stay current on new technologies, and make career-advancing connections with peers.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends Future Labs Live USA 2023 on October 4-5, 2023
October 4, 2023
Branford, CT
Enrich Biosystems is excited to join Future Labs Live USA 2023 in Pennsylvania Convention Center, PA on October 4-5. See our booth in Start-up Zone and learn how TROVO enables discovering meaningful clones on cell research laboratories. Enrich Biosystems is proud to demonstrate how it supported the researchers from academic labs to industrial settings.
Future Labs Live USA 2023 captures all elements of the laboratory, from fundamental scientific breakthroughs to the latest technological advancements, we will be joining in two full days of collaboration, innovation, and networking, along with 150+ speakers across the United States from the world’s most prestigious laboratories.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems to Present at BioPharm America 2023
September 8, 2023
Branford, CT
Enrich Biosystems Inc., today announced that it will be presenting in-person at BioPharm America, taking place September 13-14, 2023, in Raleigh, North Carolina. BioPharm America brings together executives from major pharmaceutical companies, biotechnology companies of every size and stage, investors, and academic institutions to engage and drive drug development further.
Enrich Biosystems has revolutionized cancer cell therapy discovery with its cutting-edge microfluidics-free technology. Enrich technology simplifies the process of cell co-culturing and kinetics profiling to conduct guided capturing based on cell behaviors and functions. Its commercial system, TROVO, uses dissolvable microwells and visual enrichment strategies on a highly integrated high-throughput platform, allowing for fast in vitro development of the “in vivo best” construct with unparalleled efficiency. TROVO tremendously impacts cell therapy research by significantly reducing process time and cost. Enrich Biosystems is selected to present as one of six “Startup Spotlight” companies on September 14th, the entire event is expected to bring together over 500 executives from biotech, pharma, and finance companies to engage in 1,500+ one-to-one meetings.
About Enrich Biosystems
Enrich Biosystems Inc., located in Branford, CT, is an early-stage biotech that excels in developing and commercializing a unique microfluidics-free cell analysis and isolation technology. This revolutionary cell technology facilitates a seamless workflow of cell coculturing, kinetics profiling, and guided capturing based on cell behaviors and functions. Enrich partners with leading research institutions and cell therapy developers to create critical applications for its platform, including T-cell, NK cell, and stem cell discovery, as well as sample processing and patient cell line development.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Joins Cell Manufacturing Research Initiative to Further Advance Cell Therapy Discovery
August 2, 2023
Branford, CT
Enrich Biosystems, a pioneering early-stage biotech company developing a unique microfluidics-free cell analysis and isolation technology, today announced it has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a consortium of universities, companies, and clinical collaborators brought together to develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Launched in 2017 with investment from NSF, the Center aims to revolutionize the treatment of cancer, heart disease, neurological disorders, and other chronic diseases by enabling the broad use of potentially curative therapies utilizing living cells.
Enrich Biosystems has revolutionized cancer cell therapy discovery with its cutting-edge microfluidics-free technology. Enrich technology simplifies the process of cell co-culturing and kinetics profiling to conduct guided capturing based on cell behaviors and functions. Its commercial system, TROVO, uses dissolvable microwells and visual enrichment strategies on a highly integrated high-throughput platform, allowing for fast in vitro development of the “in vivo best” construct with unparalleled efficiency. TROVO tremendously impacts cell therapy research by significantly reducing process time and cost.
“We are pleased to welcome Enrich Biosystems as a CMaT industry member to our initiative,” said Johnna Temenoff, Director of CMaT and the Carol Ann and David D. Flanagan Professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. “By partnering with the Enrich team, we aim to improve the current processes of discovery and manufacturing for critical cell therapies. As a result, patients requiring cell therapy could receive them faster. We are excited about the potential future clinical impact of this work.”
“The Enrich team is thrilled and proud to join the CMaT community,” said Dong Wang, CEO at Enrich Biosystems. “It is great to receive recognition for our technology’s ability to standardize cell discovery and manufacturing QC processes, including pooled cytotoxicity and persistence screening, potency measurement, and functional percentage monitoring. TROVO’s unmatched technical features make it a game-changer for the cutting-edge discovery of cell therapy.”
Beyond Georgia Tech, CMaT includes major university partners – the University of Georgia, the University of Wisconsin-Madison, and the University of Puerto Rico, Mayaguez Campus – as well as affiliate partners such as the University of Pennsylvania, Emory University, University of Oregon, and the Morgridge Institute for Research. Additional international academic partners from Canada, Ireland, and Japan, as well as industry and the U.S. national laboratories, are critical collaborators.
About Enrich Biosystems
Enrich Biosystems Inc., located in Branford, CT, is an early-stage biotech that excels in developing and commercializing a unique microfluidics-free cell analysis and isolation technology. This revolutionary cell technology facilitates a seamless workflow of cell coculturing, kinetics profiling, and guided capturing based on cell behaviors and functions. Enrich partners with leading research institutions and cell therapy developers to create critical applications for its platform, including T-cell, NK cell, and stem cell discovery, as well as sample processing and patient cell line development.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends ISSCR 2023 on June 14-17, 2023
June 14, 2023
Branford, CT
Enrich Biosystems is excited to join the 2023 ISSCR (The International Society for Stem Cell Research) annual meeting in Boston on June 14-17. See us at booth number 1026 and learn how TROVO enables discovering meaningful clones on stem cell work. Enrich Biosystems is proud to demonstrate how it supported the researchers from Yale Stem Cell Center for their fascinating projects with a substantial contribution from Enrich technology.
The world’s best and brightest in stem cell research and regenerative medicine convene once a year for the ISSCR Annual Meeting, join more than 4,000 scientists from around the globe at ISSCR 2023 to take part in a 4-day program comprising the year’s most significant new advances in the field.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Biosystems Attends PEGS Boston 2023 on May 15-19
May 15, 2023
Branford, CT
Enrich Biosystems is excited to speak at PEGS Boston on May 15. We introduce how our microfluidics-free TROVO instrument and cell therapy discovery workflow addresses the known gap in existing screening technologies for CART, TIL, TCR, and NK to recapitulate in vivo biology. Enrich Biosystems is proud to offer a cell screening technology that has been demonstrated to identify and isolate the most active in vivo CAR T constructs.
PEGS Boston Summit is the leading biologics event with comprehensive programming covering all aspects of biologic drug development with in-depth presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytics, immunogenicity, and more.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich changes its name to better present the business
November 9, 2022
Branford, CT
Enrich Biosystems has recently changed the company name from Enrich Therapeutics Inc. to Enrich Biosystems Inc. This change took effect on November 9th, 2022.
Please note that there has been no change in management and the range of products/services we offer. As a biotech/life science tool company, this change will allow us to present our core values in a better way.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Therapeutics Awarded NCI Research Contract to Accelerate the Development of Advanced Sample Processing Platforms for Downstream Single-Cell Multi-Omic Analysis
September 19, 2022
Branford, CT
Enrich Therapeutics Inc. a biotech company focusing on unique microfluidics-free cell discovery and isolation technology, announced today that the company had been awarded a 12-month Small Business Innovation Research (SBIR) research contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for further development of this critical application on cell/tissue sample processing with its proprietary cell isolation technology. This project will be performed in collaboration with Dr. Kien Pham’s team from Yale Pathology Dept.
Single cell multimodal omics (scMulti-omics) technologies by integrating different readouts, such as DNA, RNA and protein expression, can provide greater value than the sum of the parts making these technologies powerful to characterize the cell in-depth. Isolation of unique cell populations, and simultaneous and selective extraction of different macromolecules can enable further experimental analyses to answer critical questions in basic science and clinical research and empower observational and therapeutic studies. By 2025, the global scMulti-omics market is anticipated to be $5.32 billion, mainly driven by the increasing need for noninvasive or minimally invasive diagnosis and personalized medicine.
Recent advances have significantly improved multi-omic analysis; however, the sample processing technologies for tumors, in particular solid tumors for multi-omic analysis, are lagging behind. The existing technologies are associated with low throughput, high cost, and sub-optimal processing affecting data quality, which hampers their widespread use in biology and ultimately in medicine. There is a need for robust sample processing technologies that are compatible with downstream analysis and can be easily integrated into the preanalytical workflow.
With this financial support from NCI, Enrich expects to provide a robust sample processing platform that could easily integrate with scMulti-omic analysis and allow a better understanding of heterogeneity in solid tumors and the microenvironment, and also enable the analysis of rare and low-abundant cells such as circulating tumor cells and antigen-presenting cells, to potentially open the door to new biomarker and therapeutic targets discoveries in cancer. development of technologies to improve single-cell multi-omic preanalytical microfluidic platforms that integrate steps of the preanalytical workflow such as sample processing, single-cell separation or isolation and enrichment, technologies for solid tumor dissociation/isolation, enrichment and tracking of cancer cells and/or biomolecules for scMulti-omics.
The research reported in this publication is supported by the National Cancer Institute, part of the National Institutes of Health, under research topic number NIH/NCI 439. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About this contract
The total amount of this contract is $ 399,761.00.
100% project cost will be financed with Federal funds.
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91022C00061.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Therapeutics Attends 7th Annual CAR-TCR Summit in Boston
September 16, 2022
Branford, CT
Enrich Therapeutics will be introducing our brand new TROVO system, a novel microfluidics-free cell discovery and isolation platform, at the 7th annual CAR-TCR Summit. Come to see us at booth D70 and find out how Enrich technology enables discovering meaningful clones.
Annual CAR-TCR Summit is the biggest CAR-TCR meeting around the world, uniting experts from the long-standing commercial giants to the trailblazing pioneers, and discover new strategies for everything from discovery to early phase development to commercialization.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Therapeutics selected to be part of the 2022 MassChallenge US early-stage accelerator program!
July 11, 2022
Branford, CT
MassChallenge has officially named the 2022 cohort for the US early-stage program, and Enrich Therapeutics Inc. is pleased to be one of them! We look forward to all we will gain throughout this program, and we’re excited to tap into the @MassChallenge global network of world-class mentors and partners.
MassChallenge is the global network for innovators. It supports entrepreneurs and startups through the early stages of building a business. Founded in 2009, MassChallenge’s mission is to equip bold entrepreneurs to disrupt the status quo and create sustainable change.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Through MassChallenge’s global network, entrepreneurs get access to industry-based mentors and resources to support every area of the startup lifecycle so they can help solve some of the world’s most massive challenges. MassChallenge’s hyper-focused, proven methodology helps founders identify goals and key initiatives, providing access to a meaningful network of experts and mentors, while also providing connection to a deep peer network from across the global community.
Enrich Therapeutics was selected for the inaugural BioTools Innovator 2021 Accelerator!
August 1, 2021
Branford, CT
BioTools Innovator, a new program run by MedTech Innovator, with a focus on accelerating life science tools and diagnostics, just announced the ten companies selected to participate in the organization’s inaugural three-month virtual mentorship-focused Accelerator program.
BioTools Innovator works closely with stakeholders across the industry to foster the growth of early to mid-stage startups. The top ten leading-edge biotechnology startups are developing solutions for cell research, genomics, data and informatics, and synthetic biology and hail from across the U.S. and Europe.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Therapeutics Inc. is honored to be chosen by BioTools Innovator as one of the top 10 leading biotech startups developing solutions to advance research & improve human health! The company looks forward to participating in the inaugural 2021 Accelerator program.
Enrich Therapeutics Attends 2021 CYTO Innovation Technology Showcase
June 1, 2021
Branford, CT
Enrich Therapeutics Inc. announced today that the company is going to present at the 2021 CYTO Innovation Showcase live on Tuesday, June 8, 2021. Enrich cell isolation technology was selected as one of the three technology showcase finalists after being qualified through vigorous competition. The CYTO Virtual Interactive 2021 conference hosts by ISAC (the International Society for the Advancement of Cytometry) on June 7-10, 2021.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Therapeutics Relocated to Independent Lab/Office Space in CT
February 15, 2021
Branford, CT
Enrich Therapeutics Inc. announced today that the company signed a lease for 5,500 square feet of independent lab and office space in Business Park of Branford, CT. It is currently setting up its new operation space and will be completely moving out of BioCT Incubator in Groton by the end of this month. This new expansion would greatly benefit the company’s team building, business operation, collaborating R&D projects, as well as investor relationships.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Therapeutics Awarded NIH Grant to Accelerate Development of its Groundbreaking Single Cell Isolation Technology
August 17, 2020
Groton, CT / Worcester, MA
Enrich Therapeutics Inc., a device and application company focusing on unique single cell isolation technology, announced today that the company has been awarded a 24-month Small Business Innovation Research (SBIR) phase II grant in the amount of $1.7 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for further development of its proprietary single cell isolation platform.
Characterizing both functional and genetic heterogeneity among a pool of cells remains a major scientific challenge in immunology, cancer research, neurobiology, and developmental biology. Isolating cells with the same phenotype is the key to understanding such heterogeneity. Enrich proprietary technology targets the huge cell isolation market valued at more than $6B in 2020, and can be used to select and isolate cells based on organelle translocation, chromatin morphology, phagocytosis, synapse formation, protein co-localization, cell-cell interactions and other time-resolved cellular behaviors which cannot be achieved by current sorting platforms in a high-throughput manner.
During SBIR phase I of this project, which the grant was awarded within 10 months since the inception of Enrich Therapeutics, the company has established a unique, non-fluidic, technology to address the aforementioned unmet needs. The Enrich team completed the alpha version of prototype design and demonstrated its utility in critical POC applications, such as blood cell removal, phage enrichment on single beads, and isolation of tumor-killing immune cell clones. All phase I milestones were fully accomplished with convincing results, and the new award is intended to facilitate the translation of this promising technology to a commercial product and ultimately provide beneficial life science innovation to global biomedical researchers.
This new grant follows the company’s successful Phase I findings and will support the ongoing work of platform optimization and product development. Enrich team is tirelessly continuing the effort to bring its technology to market, besides the device, the company is planning to launch two accompanying application kits, Enrich-Live and Enrich-Seq, to unify the fragmented cell isolation market. The successful commercialization of Enrich products will enable thousands of cell biology labs and clinical settings to manipulate single cells as well as desired cell combinations on their computer screens with much-reduced cost and superior outcome.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
The research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under Award Number R44AI147734. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Enrich Therapeutics Inc. Secures Seed Funding from Connecticut Innovations and other Angel Investors
July 15, 2020
Groton, CT / Worcester, MA
Enrich therapeutics Inc. (founded in 2018), a device and application company focusing in unique single cell isolation technology, announced today that it successfully closed $320k in seed funding. The round was led by Connecticut Innovations, with participation from other angel investors in Boston Harbor Angels and Teich Technology Investments. This fund will support the ongoing development of Enrich’s proprietary single cell isolation platform.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Therapeutics develops NIAID funded novel single cell isolation platform to enhance global biomedical research at true single cell level with superior affordability and strength. Its static cell capture technology enables clone isolation under desired micro-environment with real-time monitoring. Enrich platform will have extensive impact in fields of basic biology, CAR-T, antibody, tumor genetics etc. Enrich team is committed to isolating single clones from any physiologically relevant scenario.
Enrich Therapeutics Opens New Lab in CT
July 1, 2019
Groton, CT / Worcester, MA
Enrich Therapeutics set up its new operating location and application development laboratory in BioCT Innovation Commons started on July 2019. This new expansion would greatly benefit our business operation, investor relationship as well as collaborating R&D projects.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Enrich Therapeutics Received SBIR Phase 1 Grant
June 3, 2019
Groton, CT / Worcester, MA
Enrich Therapeutics has been awarded a Small Business Innovation Research (SBIR) phase 1 grant from National Institute of Health (NIH) in June 2019. The award will support our expedited development of disruptive single cell isolation platform as well as integrated novel applications.
For more information:
Investor Contact:
investors@enrichtbio.com
General Contact:
inquiry@enrichbio.com
Welcome to Enrich Therapeutics!
January 1, 2019
Groton, CT / Worcester, MA
